Zoledronic acid compared with pamidronate in patients with prostate cancer and bone metastases: Effects on skeletal complications and bone markers

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases
    Feng Wang
    Wei Chen
    Hongde Chen
    Licai Mo
    Haiyong Jin
    Zhixian Yu
    Chengdi Li
    Qing Liu
    Feifei Duan
    Zhiliang Weng
    [J]. Medical Oncology, 2013, 30
  • [32] Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
    Yu, A. P.
    Namjoshi, M.
    Xie, J.
    Parikh, K.
    Wu, E. Q.
    Guo, A.
    Culver, K. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Coleman, RE
    Major, P
    Lipton, A
    Brown, JE
    Lee, KA
    Smith, M
    Saad, F
    Zheng, M
    Hei, YJ
    Seaman, J
    Cook, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4925 - 4935
  • [34] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, M.
    Botteman, M. F.
    Kaura, S.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 132 - 132
  • [35] Rapid effects of zoledronic acid in reducing bone complications in patients with bone metastases in the first 3 months of treatment
    Saad, F.
    Chen, Y. M.
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 : S51 - S52
  • [36] Re: Economic Evaluation of Denosumab Compared With Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients With Bone Metastases
    Schmid, Hans-Peter
    Theiler, Robert
    [J]. EUROPEAN UROLOGY, 2012, 61 (02) : 427 - 428
  • [37] Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid
    Lipton, A
    Colombo-Berra, A
    Bukowski, RM
    Rosen, L
    Zheng, M
    Urbanowitz, G
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6397S - 6403S
  • [38] The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
    Hadji, Peyman
    Ziller, May
    Maurer, Tobias
    Autenrieth, Michael
    Muth, Mathias
    Ruebel, Amelie
    May, Christoph
    Birkholz, Katrin
    Diebel, Erhardt
    Gleissner, Jochen
    Rothe, Peter
    Gschwend, Juergen E.
    [J]. JOURNAL OF BONE ONCOLOGY, 2012, 1 (03) : 88 - 94
  • [39] Zoledronic acid and atrial fibrillation in cancer patients with bone metastases
    Aksoy, S.
    Dizdar, O.
    Turgut, D.
    Dede, D. Sener
    Arslan, C.
    Harputluoglu, H.
    Altundag, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    Chen, TL
    Berenson, J
    Vescio, R
    Swift, R
    Gilchick, A
    Goodin, S
    LoRusso, P
    Ma, PM
    Ravera, C
    Deckert, F
    Schran, H
    Seaman, J
    Skerjanec, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1228 - 1236
12345